Home / Letter From The Editor / Nov. 21, 2020

Nov. 21, 2020

Nov 21, 2020

More than a few years ago I was on the international advisory board for Lilly, and the head of the board was Dr. Dan Pollom. We became friends and over the years he has been involved in a lot of great research at Lilly. He recently has been working on the use of CGM devices, TIR and the value of postprandial glucose levels. He has looked at this for the reduction of CVD in patients, and how adding Lilly’s new rapid acting insulin can improve outcomes.

This week our LECOM College of Pharmacy intern, Tarshay Boyd, has culled out the most important parts of an interview with Dr. Pollom for your review in our Laterpay feature.




We can make a difference!


Dave Joffe